140 related articles for article (PubMed ID: 7906243)
1. The effects of CV205-502 in patients with hyperprolactinaemia intolerant and/or resistant to bromocriptine.
Razzaq R; O'Halloran DJ; Beardwell CG; Shalet SM
Horm Res; 1993; 39(5-6):218-22. PubMed ID: 7906243
[TBL] [Abstract][Full Text] [Related]
2. Quinagolide efficacy and tolerability in hyperprolactinaemic patients who are resistant to or intolerant of bromocriptine.
Vilar L; Burke CW
Clin Endocrinol (Oxf); 1994 Dec; 41(6):821-6. PubMed ID: 7889620
[TBL] [Abstract][Full Text] [Related]
3. A double-blind study comparing a new non-ergot, long-acting dopamine agonist, CV 205-502, with bromocriptine in women with hyperprolactinaemia.
Homburg R; West C; Brownell J; Jacobs HS
Clin Endocrinol (Oxf); 1990 May; 32(5):565-71. PubMed ID: 1973085
[TBL] [Abstract][Full Text] [Related]
4. CV 205-502, a new dopamine agonist, versus bromocriptine in the treatment of hyperprolactinaemia.
van der Heijden PF; de Wit W; Brownell J; Schoemaker J; Rolland R
Eur J Obstet Gynecol Reprod Biol; 1991 Jul; 40(2):111-8. PubMed ID: 1676973
[TBL] [Abstract][Full Text] [Related]
5. Endocrine function, psychiatric and clinical consequences in patients with macroprolactinomas after long-term treatment with the new non-ergot dopamine agonist CV205-502.
Barnett PS; Palazidou E; Miell JP; Coskeran PB; Butler J; Dawson JM; Maccabe J; McGregor AM
Q J Med; 1991 Nov; 81(295):891-906. PubMed ID: 1687293
[TBL] [Abstract][Full Text] [Related]
6. Long-term treatment with a new non-ergot long-acting dopamine agonist, CV 205-502, in women with hyperprolactinaemia.
Rasmussen C; Bergh T; Wide L; Brownell J
Clin Endocrinol (Oxf); 1988 Sep; 29(3):271-9. PubMed ID: 2908030
[TBL] [Abstract][Full Text] [Related]
7. Effect of CV 205-502 in hyperprolactinaemic patients intolerant of bromocriptine.
Newman CB; Hurley AM; Kleinberg DL
Clin Endocrinol (Oxf); 1989 Oct; 31(4):391-400. PubMed ID: 2576397
[TBL] [Abstract][Full Text] [Related]
8. Acute and long-term effects of once-daily oral bromocriptine and a new long-acting non-ergot dopamine agonist, quinagolide, in the treatment of hyperprolactinemia: a double-blind study.
Verhelst JA; Froud AL; Touzel R; Wass JA; Besser GM; Grossman AB
Acta Endocrinol (Copenh); 1991 Oct; 125(4):385-91. PubMed ID: 1683503
[TBL] [Abstract][Full Text] [Related]
9. Positive response to compound CV 205-502 in hyperprolactinemic patients resistant to or intolerant of bromocriptine.
Merola B; Sarnacchiaro F; Colao A; Di Somma C; Di Sarno A; Ferone D; Selleri A; Landi ML; Schettini G; Nappi C
Gynecol Endocrinol; 1994 Sep; 8(3):175-81. PubMed ID: 7847102
[TBL] [Abstract][Full Text] [Related]
10. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group.
Webster J; Piscitelli G; Polli A; Ferrari CI; Ismail I; Scanlon MF
N Engl J Med; 1994 Oct; 331(14):904-9. PubMed ID: 7915824
[TBL] [Abstract][Full Text] [Related]
11. CV205-502, a new non-ergot dopamine agonist, reduces prolactinoma size in man.
Barnett PS; Dawson JM; Butler J; Coskeran PB; Maccabe JJ; McGregor AM
Clin Endocrinol (Oxf); 1990 Aug; 33(2):307-16. PubMed ID: 1977537
[TBL] [Abstract][Full Text] [Related]
12. Quinagolide--a valuable treatment option for hyperprolactinaemia.
Barlier A; Jaquet P
Eur J Endocrinol; 2006 Feb; 154(2):187-95. PubMed ID: 16452531
[TBL] [Abstract][Full Text] [Related]
13. CV 205-502--effectiveness, tolerability, and safety over 24-month study.
Shoham Z; Homburg R; Jacobs HS
Fertil Steril; 1991 Mar; 55(3):501-6. PubMed ID: 1672113
[TBL] [Abstract][Full Text] [Related]
14. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation.
Webster J
Drug Saf; 1996 Apr; 14(4):228-38. PubMed ID: 8713691
[TBL] [Abstract][Full Text] [Related]
15. Current treatment issues in female hyperprolactinaemia.
Crosignani PG
Eur J Obstet Gynecol Reprod Biol; 2006 Apr; 125(2):152-64. PubMed ID: 16288952
[TBL] [Abstract][Full Text] [Related]
16. Treatment of amenorrhoea, galactorrhoea and hypogonadism with bromocriptine.
Donald RA; Espiner EA; Livesey JH
Aust N Z J Med; 1978 Jun; 8(3):262-6. PubMed ID: 279321
[TBL] [Abstract][Full Text] [Related]
17. CV 205-502 treatment of macroprolactinomas.
Crottaz B; Uske A; Reymond MJ; Rey F; Siegel RA; Brownell J; Gomez F
J Endocrinol Invest; 1991 Oct; 14(9):757-62. PubMed ID: 1684803
[TBL] [Abstract][Full Text] [Related]
18. Neuroleptic-associated hyperprolactinemia. Can it be treated with bromocriptine?
Smith S
J Reprod Med; 1992 Aug; 37(8):737-40. PubMed ID: 1359137
[TBL] [Abstract][Full Text] [Related]
19. The effect of two dopaminergic drugs on menstrual function and psychological state in hyperprolactinemia.
Lappöhn RE; van de Wiel HB; Brownell J
Fertil Steril; 1992 Aug; 58(2):321-7. PubMed ID: 1353028
[TBL] [Abstract][Full Text] [Related]
20. The efficacy and tolerability of CV 205-502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine.
van der Lely AJ; Brownell J; Lamberts SW
J Clin Endocrinol Metab; 1991 May; 72(5):1136-41. PubMed ID: 1673685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
